• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: FISHER & PAYKEL HEALTHCARE LTD OPTIFLOW + ADULT NASAL CANNULA; BTT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

FISHER & PAYKEL HEALTHCARE LTD OPTIFLOW + ADULT NASAL CANNULA; BTT Back to Search Results
Model Number MYOPT9MEDIUM
Device Problem Disconnection (1171)
Patient Problem Insufficient Information (4580)
Event Date 06/23/2022
Event Type  malfunction  
Manufacturer Narrative
(b)(4).Product background: the myopt9medium is a nasal cannula patient interface for delivery of humidified respiratory gases, including those who are receiving nasal high flow therapy (nhf).Optiflow + interfaces are designed for use with the myairvo 2 series of humidification devices.Nhf therapy and the myairvo 2 device are intended for use with spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.The myairvo 2 device should not be used for life support purposes and appropriate patient monitoring must be used at all times.The cannula consists of a lightweight delivery tube connected to a rigid plastic base and soft nasal prongs (nasal interface).This allows the device to be light weight and durable.The interface is held in place by a head strap and features a head strap clip which works in tandem with the tubing clip (attaches to the patient's clothing/bedding) to support the weight of the circuit and prevent the cannula being dislodged.Fisher & paykel healthcare (f&p) has requested further information regarding the reported event including the device setup, sequence of events, the relevant medical history and medical cause of death.Furthermore, the complaint myopt9medium optiflow + adult nasal cannula and myairspiral heated breathing tube are currently en route to f&p for evaluation.We will provide a follow up report upon completion of our investigation.
 
Event Description
A distributor in japan reported on the morning of (b)(6) 2022, it was discovered that the patient was not breathing and it was reported that the myoepithelium optiflow+ nasal cannula was found disconnected from the myairspiral heated breathing tube when in use with the myairvo2.From the (b)(6) 2022 the patient had been using oxygen during the day and switched to myairvo 2 at night at home, with no problems with the myairvo 2.The patient had advanced stage colon cancer, non-tuberculous mycobacterium tuberculosis and respiratory failure.It was further reported the patient deceased, however the attending physicians opinion was that the patient had likely deceased due to advanced stage colon cancer.Further information has been requested regarding the reported event, including the return of the devices.
 
Manufacturer Narrative
(b)(4).Product background: the myopt9medium is a nasal cannula patient interface for delivery of humidified respiratory gases, including those who are receiving nasal high flow therapy (nhf).Optiflow + interfaces are designed for use with the myairvo 2 series of humidification devices.Nhf therapy and the myairvo 2 device are intended for use with spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.The myairvo 2 device should not be used for life support purposes and appropriate patient monitoring must be used at all times.The cannula consists of a lightweight delivery tube connected to a rigid plastic base and soft nasal prongs (nasal interface).The interface is held in place by a head strap and features a head strap clip which works in tandem with the tubing clip (attaches to the patient's clothing/bedding) to support the weight of the circuit and prevent the cannula being dislodged.Method: the complaint myopt9medium optiflow + adult nasal cannula and myairspiral heated breathing were returned to fisher & paykel healthcare (f&p) new zealand for investigation, where they were inspected.An investigation was carried out by f&p which was based on the information provided by the healthcare facility, our evaluation of the returned devices, and our knowledge of the product.Results: further information about the reported incident and the medical cause of death was requested from the healthcare facility.However, the healthcare facility did not provide any of the requested information despite several attempts to request this.The healthcare facility had reported the following sequence of events: from the (b)(6) 2022 a patient had been using oxygen during the day and switched to myairvo 2 at night at home, with no problems with the myairvo 2.The patient had advanced stage colon cancer, non-tuberculous mycobacterium tuberculosis and respiratory failure.On the morning of (b)(6) 2022, it was discovered that the patient was not breathing, and it was reported that the myopt9medium optiflow+ nasal cannula was found disconnected from the myairspiral heated breathing tube when in use with the myairvo2.It was further reported the patient deceased, however the attending physician's opinion was that the patient had likely deceased due to advanced stage colon cancer.Visual inspection of the returned myopt9medium optiflow+ nasal cannula and the myairspiral heated breathing tube revealed no damage to the devices.The force required to disconnect the myopt9medium optiflow+ nasal cannula and the myairspiral heated breathing tube was measured, and this was within specification.No fault was found with either device.The lot number for either device was not provided, therefore the specific device history records (dhrs) were unable to be reviewed.However, the dhrs are reviewed for every manufactured lot as part of the final quality control checks at the completion of the assembly process.Therefore, the subject myopt9medium optiflow+ nasal cannula and myairspiral heated breathing tube would have met all specifications at the time of release.Conclusion: we are unable to determine what caused the reported event, as no fault was found with either device.In addition, the device set up had been in use overnight, for a period of 22 days without incident.Fisher and paykel healthcare's manufacturing controls for the optiflow + tubing include inspections during production for visual defects including cracks, tears, moulding defects, contamination, inclusions, discoloration and stretching or deformation.The optiflow + tubing is also inspected for any assembly defects, including confirmation the swivel and 3-way connector are connected with the correct engagement.The user instructions which accompany the optiflow + adult nasal cannula show in pictorial format the correct placement and fitting of the cannula, including ensuring the headstrap clip and the tubing clip are appropriately attached.The user instructions also warn: - "ensure head strap clip is attached, to prevent cannula from being pulled out of the nares." - "cannula can become unattached if not used with the head strap clip." - "attach tubing clip to clothing/bedding to prevent cannula from pulling off face." - "appropriate patient monitoring must be used at all times.Failure to monitor the patient may result in loss of therapy, serious injury or death - "failure to use the set-up described above can compromise performance and affect patient safety".
 
Event Description
A distributor in japan reported on the morning of (b)(6) 2022, it was discovered that the patient was not breathing and it was reported that the myopt9medium optiflow+ nasal cannula was found disconnected from the myairspiral heated breathing tube when in use with the myairvo2.From the (b)(6) 2022 the patient had been using oxygen during the day and switched to myairvo 2 at night at home, with no problems with the myairvo 2.The patient had advanced stage colon cancer, non-tuberculous mycobacterium tuberculosis and respiratory failure.It was further reported the patient deceased, however the attending physicians opinion was that the patient had likely deceased due to advanced stage colon cancer.Further information about the reported incident and the medical cause of death was requested from the healthcare facility.However, the healthcare facility did not provide any of the requested information despite several attempts to request this.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTIFLOW + ADULT NASAL CANNULA
Type of Device
BTT
Manufacturer (Section D)
FISHER & PAYKEL HEALTHCARE LTD
15 maurice paykel place
east tamaki
auckland, 2013
NZ  2013
Manufacturer (Section G)
FISHER & PAYKEL HEALTHCARE LTD
15 maurice paykel place
east tamaki
auckland, 2013
NZ   2013
Manufacturer Contact
faranak gomarooni
17400 laguna canyon road
suite 300
irvine, CA 92618
9494534000
MDR Report Key15080778
MDR Text Key297231579
Report Number9611451-2022-00640
Device Sequence Number1
Product Code BTT
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K162553
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Distributor
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 06/23/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberMYOPT9MEDIUM
Device Catalogue NumberMYOPT9MEDIUM
Was Device Available for Evaluation? Device Returned to Manufacturer
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received 06/23/2022
Initial Date FDA Received07/21/2022
Supplement Dates Manufacturer Received08/28/2022
Supplement Dates FDA Received09/27/2022
Was Device Evaluated by Manufacturer? Yes
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age73 YR
-
-